TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients : vimarsana.com

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Boston , Massachusetts , United States , South Korea , Seongnam , Kyonggi Do , Italy , Spain , Spanish , Italian , Tiumbio Kosdaq , Suna Cho , Junseok Jang , Corporate Communications Investor Relations , International Society On Thrombosis , Prnewswire Tiumbio Co Ltd , Head Of Corporate Communications Investor Relations , Linkedin , Novo Nordisk , Italian Medicines Agency , Spanish Agency Of Medicines , Tiumbio Co Ltd , Clinical Trial , Long Acting Recombinant Activated Factor , International Society , Clinical Trial Application , Spanish Agency , Medical Products , Hun Taek Kim , Corporate Communications ,